Bicara Therapeutics Inc. 8-K Report: Key Updates on January 13, 2025
Based on the provided section of the financial report, here are the key pieces of information extracted:
- Entity Information:
- Company Name: Bicara Therapeutics Inc.
- CIK (Central Index Key): 0002023658
- SEC File Number: 001-42271
- Tax Identification Number (TIN): 85-2903745
- Address: 116 Huntington Avenue, Suite 703, Boston, MA 02116
- Contact Number: (617) 468-4219
- Filing Information:
- Form Type: 8-K (Current report)
- Filing Date: January 13, 2025
- Stock Information:
- Type of Security: Common Stock
- Par Value: $0.0001
- Stock Symbol: BCAX
- Exchange: NASDAQ
- Period of Report:
- Report Period Start Date: January 13, 2025
- Report Period End Date: January 13, 2025
Insights:
- The filing is an 8-K, which typically indicates a significant event or material change affecting the company that shareholders need to be informed about.
- The report is for a single day, suggesting it may pertain to an event that occurred on that date, such as a major announcement or corporate action.
- The company is publicly traded on NASDAQ, which implies a level of regulatory scrutiny and compliance requirements.
- The par value of the common stock is low, indicating a typical structure for many startups or biotech firms, which might be in early stages of development.
This information is crucial for investors, analysts, and stakeholders assessing the company's current activities and regulatory compliance.